updated 9/20/2010 12:46:32 PM ET 2010-09-20T16:46:32

RICHMOND, British Columbia, Sept. 20, 2010 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) CEO Dr. Ricardo Moro recently presented at the meeting of the International Society of Oncology and BioMarkers (ISOBM) held on Sept. 10, 2010 in Munich, Germany. The meeting was broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics. Dr. Moro made two presentations related to the Company's broad spectrum cancer marker, RECAF™, that is increased in the blood of cancer patients.

"This was a very important meeting for BioCurex because of the interest elicited by our presentations," said Dr. Moro. "The potential to monitor recurrence and perhaps the effectiveness of cancer therapy using only one blood test for all types of cancer makes the RECAF test broadly appealing. Also, the fact that RECAF can detect cancers such as breast cancer, for which there are no good alternative markers, makes it more attractive."

The first presentation described the decrease in RECAF following removal of the tumor by surgery. These results together with other data indicate that the RECAF test can be used to monitor therapy and recurrence in cancer patients. 

The second presentation discussed the statistical validation of new cancer markers based on the experience gathered while developing RECAF. Dr. Moro was asked to co-author a paper setting up guidelines related to the statistical validation of new tumor markers.

About BioCurex, Inc.

BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.

RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells.  It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.  

BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Inverness Medical Innovations. For further information on these agreements visit:  
http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt .

For more information about the Company, please visit www.BioCurex.com .
 
For more information about OncoPet Diagnostics Inc., please visit:
www.OncoPetDiagnostics.com .

Forward-Looking Statements

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.79%
$30K home equity loan FICO 5.78%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com